Literature DB >> 657688

Pharmacokinetics of oral acetylcysteine: absorption, binding and metabolism in patients with respiratory disorders.

D Rodenstein, A DeCoster, A Gazzaniga.   

Abstract

The fate of an oral 100 mg dose of 35S-acetylcysteine, a mucolytic agent, was studied in 10 patients with respiratory disorders, 5 of whom underwent pneumonectomy or lobectomy a few hours after administration of the drug. In the 5 nonoperated patients, plasma radioactivity concentrations were maximal after 2 to 3 hours and remained high after 24 hours; about 22% of radioactivity was excreted in urine after 24 hours. In the 5 operated patients, plasma radioactivity concentrations were comparable with those in the nonoperated patients. Lung tissue radioactivity concentrations after 5 hours were comparable with those in plasma, while the presence of small amounts of radioactivity in the bronchial secretions indicates that acetylcysteine passes into the mucus. Total radioactivity after 5 hours consisted of free, unchanged drug and metabolites (about 22% of total in plasma, 48% in lung tissue), unchanged drug bound to protein by means of labile disulphide bridges (about 14% in plasma, 47% in lung tissue), and drug firmly bound to protein (about 64% in plasma, 5% in lung tissue). Oral acetylcysteine is rapidly absorbed and slowly excreted and is available in the lung in an active form for at least 5 hours at high concentrations.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 657688     DOI: 10.2165/00003088-197803030-00005

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  8 in total

1.  The reduction in vitro in viscosity of mucoprotein solutions by a new mucolytic agent, N-acetyl-L-cysteine.

Authors:  A L SHEFFNER
Journal:  Ann N Y Acad Sci       Date:  1963-03-30       Impact factor: 5.691

2.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

3.  Clinical evaluation of systemic acetylcysteine by different routes of administration.

Authors:  C Grassi; G C Morandini; G Frigerio
Journal:  Curr Ther Res Clin Exp       Date:  1973-04

4.  [Controlled studies of the clinical effects of acetylcysteine in oral administration in respiratory infections in pediatrics].

Authors:  G Biscatti; M Bruschelli; G Damonte; F Capozzi
Journal:  Minerva Pediatr       Date:  1972-07-28       Impact factor: 1.312

5.  Mucolytic and antibiotic effect of a new compound in chronic bronchitis.

Authors:  H Bŭrgi
Journal:  Chemotherapy       Date:  1975       Impact factor: 2.544

6.  Metabolic studies with acetylcysteine.

Authors:  A L Sheffner; E M Medler; K R Bailey; D G Gallo; A J Mueller; H P Sarett
Journal:  Biochem Pharmacol       Date:  1966-10       Impact factor: 5.858

7.  A controlled trial of intermittent oral acetylcysteine in the long-term treatment of chronic bronchitis.

Authors:  C Grassi; G C Morandini
Journal:  Eur J Clin Pharmacol       Date:  1976-03-22       Impact factor: 2.953

8.  Effect of thiols in biological systems on protein sulfhydryl content.

Authors:  A Lorber; C C Chang; D Masuoka; I Meacham
Journal:  Biochem Pharmacol       Date:  1970-05       Impact factor: 5.858

  8 in total
  14 in total

1.  Pharmacokinetics and bioavailability of reduced and oxidized N-acetylcysteine.

Authors:  B Olsson; M Johansson; J Gabrielsson; P Bolme
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

2.  Repeated-Dose Oral N-Acetylcysteine in Parkinson's Disease: Pharmacokinetics and Effect on Brain Glutathione and Oxidative Stress.

Authors:  Lisa D Coles; Paul J Tuite; Gülin Öz; Usha R Mishra; Reena V Kartha; Kathleen M Sullivan; James C Cloyd; Melissa Terpstra
Journal:  J Clin Pharmacol       Date:  2017-09-22       Impact factor: 3.126

3.  Chronic administration of N-acetylcysteine fails to prevent nitrate tolerance in patients with stable angina pectoris.

Authors:  J C Hogan; M J Lewis; A H Henderson
Journal:  Br J Clin Pharmacol       Date:  1990-10       Impact factor: 4.335

4.  The disposition and kinetics of intravenous N-acetylcysteine in patients with paracetamol overdosage.

Authors:  L F Prescott; J W Donovan; D R Jarvie; A T Proudfoot
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

5.  Bioavailability of suckable tablets of oral N-acetylcysteine in man.

Authors:  M De Bernardi di Valserra; G Mautone; E Barindelli; P Lualdi; F Feletti; M R Galmozzi
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

Review 6.  Clinical pharmacokinetics of N-acetylcysteine.

Authors:  M R Holdiness
Journal:  Clin Pharmacokinet       Date:  1991-02       Impact factor: 6.447

7.  A double-blind placebo controlled trial with oral ambroxol and N-acetylcysteine for mucolytic treatment in cystic fibrosis.

Authors:  F Ratjen; R Wönne; H G Posselt; B Stöver; D Hofmann; S W Bender
Journal:  Eur J Pediatr       Date:  1985-11       Impact factor: 3.183

8.  Pharmacokinetics of N-acetylcysteine in man.

Authors:  L Borgström; B Kågedal; O Paulsen
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

9.  N-acetylcysteine as an antidote in methylmercury poisoning.

Authors:  N Ballatori; M W Lieberman; W Wang
Journal:  Environ Health Perspect       Date:  1998-05       Impact factor: 9.031

Review 10.  The role for N-acetylcysteine in the management of COPD.

Authors:  P N R Dekhuijzen; W J C van Beurden
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2006
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.